<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004654</url>
  </required_header>
  <id_info>
    <org_study_id>199/11799</org_study_id>
    <secondary_id>YALESM-8191</secondary_id>
    <nct_id>NCT00004654</nct_id>
  </id_info>
  <brief_title>Phase III Randomized, Placebo-Controlled, Crossover Study of Soy Protein Isolate for Hereditary Hemorrhagic Telangiectasia</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Office of Rare Diseases (ORD)</source>
  <brief_summary>
    <textblock>
      OBJECTIVES: I. Evaluate migraine prophylaxis with soy protein isolate in patients with&#xD;
      hereditary hemorrhagic telangiectasia.&#xD;
&#xD;
      II. Assess whether soy protein isolate reduces the frequency and severity of epistaxis and&#xD;
      gastrointestinal bleeding in these patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE: This is a randomized study. One group of patients is treated with soy&#xD;
      protein isolate for 12 weeks. The control group receives a placebo for 12 weeks.&#xD;
&#xD;
      Patients cross to the alternate group following a 4-week washout.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 1996</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>60</enrollment>
  <condition>Hereditary Hemorrhagic Telangiectasia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>soy protein isolate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Hereditary hemorrhagic telangiectasia (HHT) with 2 of the following:&#xD;
&#xD;
          -  First-degree relative with HHT&#xD;
&#xD;
          -  History of recurrent epistaxis or gastrointestinal bleeding&#xD;
&#xD;
          -  Three or more skin telangiectasia&#xD;
&#xD;
          -  Migraine headache meeting International Headache Society criteria 3 or more times a&#xD;
             month for more than 1 year&#xD;
&#xD;
          -  No pattern of daily headaches&#xD;
&#xD;
          -  No severe head trauma&#xD;
&#xD;
          -  No onset of headaches after 50 years of age&#xD;
&#xD;
          -  At least 1 month since migraine prophylaxis&#xD;
&#xD;
          -  At least 1 month since any of the following medications: Beta blockers; Calcium&#xD;
             channel blockers; Divalproex sodium; Tricyclic antidepressants; Selective serotonin&#xD;
             re-uptake inhibitors&#xD;
&#xD;
          -  Concurrent regular treatment for migraine and gastrointestinal hemorrhage allowed&#xD;
&#xD;
          -  Creatinine no greater than 2.5 g/dL&#xD;
&#xD;
          -  No allergy to soy&#xD;
&#xD;
          -  No pregnant women&#xD;
&#xD;
          -  No women with intent to become pregnant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joshua R. Korzenik</last_name>
    <role>Study Chair</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <verification_date>December 2001</verification_date>
  <study_first_submitted>February 24, 2000</study_first_submitted>
  <study_first_submitted_qc>February 24, 2000</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2000</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>genetic diseases and dysmorphic syndromes</keyword>
  <keyword>hematologic disorders</keyword>
  <keyword>hereditary hemorrhagic telangiectasia</keyword>
  <keyword>rare disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telangiectasis</mesh_term>
    <mesh_term>Telangiectasia, Hereditary Hemorrhagic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

